Bıçakçı Nilüfer, Elli Murat
University of Health Sciences Turkey, Samsun Training and Research Hospital, Clinic of Nuclear Medicine, Samsun, Turkey.
İstanbul Medipol University Faculty of Medicine, Department of Pediatric Oncology, İstanbul, Turkey.
Mol Imaging Radionucl Ther. 2021 Feb 9;30(1):18-27. doi: 10.4274/mirt.galenos.2020.64436.
The aim of the study was to evaluate the utility of fluorine-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, restaging, and treatment response of childhood malignancies.
This study included 52 patients (32 boys, 20 girls) who were referred to our clinic between November 2008 and December 2018 with the diagnosis of malignancy. The patients were evaluated retrospectively. Median age of the patients was 13 years (range 2-17). F-FDG was given to the patients intravenously, and time of flight with PET/16 slice CT was performed 1 hour thereafter. The lowest dose was 2 mCi (74 MBq) and the highest dose was 10 mCi (370 MBq). Fasting blood sugars of all patients were found below 200 mg/dL (11.1 mmol/L).
F-FDG PET/CT was performed to evaluate the response to treatment in 38 of 52 children, staging in 11 patients (staging and evaluation of the response to treatment in nine of them), restaging in 2 patients, restaging, and evaluation of the response to treatment in 1 patient. F-FDG PET/CT examination was reported as normal in 13 patients (5 girls, 8 boys). The pathological F-FDG uptake was detected in 39 patients (14 girls, 25 boys), which indicated metastasis and/or recurrence of the primary disease. Total number of deaths was 30 (13 girls, 17 boys).
F-FDG PET/CT has a significant role for staging, restaging, treatment response, and detection of metastatic disease but it is limited for the early diagnosis of childhood cancers.
本研究旨在评估氟脱氧葡萄糖（F-FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）在儿童恶性肿瘤诊断、分期、再分期及治疗反应评估中的应用价值。
本研究纳入了2008年11月至2018年12月期间因恶性肿瘤诊断转诊至我院门诊的52例患者（32例男孩，20例女孩）。对患者进行回顾性评估。患者的中位年龄为13岁（范围2-17岁）。向患者静脉注射F-FDG，1小时后进行PET/16层CT飞行时间扫描。最低剂量为2mCi（74MBq），最高剂量为10mCi（370MBq）。所有患者的空腹血糖均低于200mg/dL（11.1mmol/L）。
52例儿童中，38例进行F-FDG PET/CT评估治疗反应，11例进行分期（其中9例同时进行分期及治疗反应评估），2例进行再分期，1例进行再分期及治疗反应评估。13例患者（5例女孩，8例男孩）的F-FDG PET/CT检查报告为正常。39例患者（14例女孩，25例男孩）检测到病理性F-FDG摄取，提示原发性疾病转移和/或复发。死亡总数为30例（13例女孩，17例男孩）。
F-FDG PET/CT在分期、再分期、治疗反应及转移疾病检测方面具有重要作用，但在儿童癌症的早期诊断方面存在局限性。
